| Excerpt | Reference |
|---|
| "Primary biliary cirrhosis is a disease of the small bile ducts with altered immunologic responsiveness often associated with various collagen diseases." | ( Schaffner, F, 1979) |
| "A patient with primary biliary cirrhosis is described." | ( Leslie, D, 1978) |
| "Focal biliary cirrhosis is an uncommon finding in infants with cystic fibrosis, but it is present in more than a fifth of surviving children and adolescents." | ( Esterly, JR; Oppenheimer, EH, 1975) |
| "Primary biliary cirrhosis is a rare chronic liver disease in Taiwan, which eventually causes mortality." | ( Chen, DS; Kao, JH; Lai, MY; Lin, JT; Sheu, JC; Sung, JL; Wang, TH; Yang, PM, 1991) |
| "Primary biliary cirrhosis is a progressive disease of the liver characterized by the immunologic destruction of bile ducts; effective therapy is lacking." | ( Baldus, WP; Dickson, ER; Homburger, HA; Jorgensen, RA; Lindor, KD; Ludwig, J; Wiesner, RH, 1990) |
| "Primary biliary cirrhosis is a chronic, destructive autoimmune liver disease of humans." | ( Coppel, RL; Gershwin, ME; McNeilage, LJ; Spithill, TW; Surh, CD; Van de Water, J; Whittingham, S, 1988) |
| "The complications of primary biliary cirrhosis are secondary to severe cholestasis, portal hypertension and progressive hepatocellular dysfunction." | ( Dabaghi, RE; Lester, R, 1986) |
| "A patient with primary biliary cirrhosis is reported in whom UV phototherapy alone was repeatedly effective in controlling severe pruritus." | ( Cerio, R; MacDonald, DM; Murphy, GM; Sladen, GE, 1987) |
| "The etiology of primary biliary cirrhosis is unknown, but the observation of (a) mitochondrial antibody, (b) elevated serum levels of IgM and (c) circulating immune complexes and (d) impaired lymphocyte transformation (- cooperation) strongly suggest, that disordered immune responses play a major role in the initiation or progression of this chronic hepatic lesion." | ( Lanzer, G; Sailer, S, 1983) |
| "Primary biliary cirrhosis is characterized by abnormalities in both cellular and humoral immunity." | ( Kapelman, B; Sacks, HS; Schaffner, F; Wolke, AM, 1984) |
| "Primary biliary cirrhosis is characterized by chronic inflammation and necrosis of the intrahepatic bile ducts and by chronic cholestasis." | ( Hoofnagle, JH; James, SP; Jones, EA; Strober, W, 1983) |
| "Primary biliary cirrhosis is a disease where small intra-hepatic bile ducts are destroyed as a result of an immunological reaction, presumably by cytotoxic T-lymphocytes on biliary epithelium." | ( Sherlock, S, 1982) |
| "The bone disease of primary biliary cirrhosis is not due to 25-hydroxyvitamin D deficiency alone and is certainly not due to a deficiency of 1,25-(OH)2D as has been postulated." | ( Goldberg, MJ; Goodman, DB; Kaplan, MM; Matloff, DS; Neer, RM, 1981) |
| "If weight loss in primary biliary cirrhosis is due to malabsorption, factors other than a reduced small intestinal bile salt concentration must be important." | ( Beckett, GJ; Dewhurst, N; Finlayson, ND; Percy-Robb, IW, 1980) |
| "Primary biliary cirrhosis is known as an autoimmune chronic cholestatic disease and characterized by various immunological abnormalities." | ( Hirano, F; Makino, I; Tanaka, H, 1993) |
| "While drug-related biliary cirrhosis is rarely fatal, this case presented an unusually rapid course of fatal biliary cirrhosis." | ( Ishii, M; Miura, M; Miyazaki, Y; Takahashi, T; Toyota, T; Ueno, Y; Yamamoto, T, 1993) |
| "sICAM-1 levels in primary biliary cirrhosis are reduced by ursodeoxycholic acid." | ( Jazrawi, RP; Levy, JH; Lim, AG; Northfield, TC; Schalm, SW; van Buuren, HR; Verma, A; Wolfhagen, FH, 1997) |
| "UDCA-treatment in primary biliary cirrhosis is now recommended in several countries, for example in the U." | ( Boberg, KM; Schrumpf, E, 1997) |
| "Primary biliary cirrhosis is an autoimmune liver disease which is characterized by the presence of autoantibodies directed against mitochondrial components which belong to the pyruvate dehydrogenase enzyme complex." | ( Boeker, KH; Gershwin, ME; Loges, S; Luettig, B; Manns, MP; Schmidt, E; Schoessler, W; Will, H; Worman, HJ, 1998) |
| "Primary biliary cirrhosis is a progressive liver disease that is believed to be autoimmune in nature." | ( Bach, N; Schaffner, F; Thung, SN, 1998) |
| "Primary biliary cirrhosis is a progressive chronic liver disease estimated to affect up to 1 in 4000 people in the UK." | ( , 1999) |
| "Primary biliary cirrhosis is a cholestatic autoimmune disease of the liver." | ( Leuschner, U, 2000) |
| "Primary biliary cirrhosis is an uncommon disease amongst Malaysians." | ( Goh, KL; Mohammed, R; Wong, NW, 1996) |
| "Primary biliary cirrhosis is a progressive autoimmune disease that affects middle aged women, resulting in liver cirrhosis." | ( Brown, B; De Giorgio, J; Jensen, WA; Jois, JA; Mackay, IR; Murphy, P; Rowley, MJ, 2000) |
| "Primary biliary cirrhosis is a rare autoimmune liver disease and an effective treatment has been difficult to establish." | ( Christensen, E; Gluud, C, 2002) |
| "Although primary biliary cirrhosis is often now diagnosed at an early stage, the diagnosis still carries important prognostic implications." | ( Chetwynd, A; James, OF; Metcalf, JV; Newman, W; Prince, M, 2002) |
| "Primary biliary cirrhosis is an enigmatic autoimmune disease of women characterized by antimitochondrial antibodies and destruction of intrahepatic bile ducts." | ( Gershwin, ME; Long, SA; Van de Water, J, 2002) |
| "Whether biliary cirrhosis is unique in triggering ET-1 and TNF-alpha alterations and HPS is unknown." | ( Fallon, MB; Ling, Y; Liu, L; Luo, B; Tang, L; Zhang, J, 2004) |
| "Primary biliary cirrhosis is a slow, progressive disease." | ( Dickson, ER; Kim, WR, 1998) |
| "Primary biliary cirrhosis is a chronic progressive cholestatic liver disease of presumed autoimmune etiology, characterised by the destruction of small intrahepatic bile ducts and the eventual development of cirrhosis and liver failure." | ( Christensen, E; Gluud, C; Prince, M, 2005) |
| "Primary biliary cirrhosis is a chronic cholestatic liver disease of unknown cause that predominantly affects middle-aged women." | ( Binaut, R; Daniel, L; Fakhouri, F; Grünfeld, JP; Knebelmann, B; Lino, M; Noël, LH; Patey, N; Rustin, P; Serpaggi, J; Vanhille, P; Varaut, A, 2005) |
| "Primary biliary cirrhosis is a chronic cholestatic liver disease with an autoimmune pathogenesis, that generally develops in adult life, often in perimenopausal age." | ( Ferrara, F; Floreani, A; Guido, M; Ostuni, PA, 2006) |
| "Primary biliary cirrhosis is an insidious disease that progresses through the clinical phases: preclinical, asymptomatic, symptomatic, and liver insufficiency." | ( Mayo, MJ, 2008) |
| "Primary biliary cirrhosis is not a contraindication to prescribe statins or fibrates to these patients." | ( Balmer, ML; Dufour, JF, 2008) |
| "Primary biliary cirrhosis is an uncommon autoimmune liver disease with unknown aetiology." | ( Christensen, E; Gluud, C; Gong, Y; Huang, ZB, 2008) |
| "Several forms of biliary cirrhosis are caused by mutations in specific genes." | ( Braun, A; Burwinkel, B; Fischer, C; Flechtenmacher, C; Gotthardt, D; Hemminki, K; Imparato, S; Keitel, V; Knisely, AS; Kubitz, R; Runz, H; Rüschendorf, F; Sauer, P; Schirmacher, P; Stiehl, A; Stremmel, W; Weiss, KH; Wirtenberger, M; Zschocke, J, 2008) |
| "Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation." | ( Abbas, G; Lindor, KD, 2010) |
| "Primary biliary cirrhosis is the archetypal autoimmune liver disease, with the disease label describing a chronic granulomatous lymphocytic small bile duct cholangitis, which now most commonly presents asymptomatically and at an early pre-cirrhotic stage." | ( Hirschfield, GM, 2011) |
| "Primary biliary cirrhosis is a hepatic auto-immune disease which is rarely associated with respiratory complications." | ( Abid, A; Alaoui-Tahiri, K; Asbaai, EH; Gharbaoui, Y; Ibn Sellam, A; Rguibi-Idrissi, M; Rhorfi-Abderrahmani, I, 2011) |
| "Treatment of primary biliary cirrhosis is complicated." | ( Bjelakovic, G; Gluud, C; Krstic, MN; Poropat, G; Rudic, JS, 2012) |
| "In recent years, primary biliary cirrhosis is mostly diagnosed in patients who are asymptomatic; however, a proportion of cases still present with typical complaints such as fatigue and/or pruritus." | ( Cassani, F; Fabbri, A; Granito, A; Lalanne, C; Lenzi, M; Masi, C; Menichella, R; Muratori, L; Muratori, P; Pappas, G; Quarneti, C, 2015) |
| "Primary biliary cirrhosis is a multifactor autoimmune disease characterized by hepatic and systemic manifestations, with immune system dysregulation and abnormalities in the hepatic metabolism of bile salts, lipids, and nutrients, as well as destruction of membrane lipids and mitochondrial dysfunction." | ( Calamita, G; Cocco, T; Grattagliano, I; Portincasa, P; Wang, DQ, 2014) |
| "Primary Biliary Cirrhosis is an immune-mediated disease in which one of the epitopes recognized by antimitochondrial autoantibodies is a lipoylated fragment of the PDC-E2 protein." | ( Nuti, F; Pacini, G; Papini, AM; Peroni, E; Rentier, C; Rovero, P, 2015) |
| "Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy." | ( Bruno, S; Carbone, M; Invernizzi, P; Mells, GF; Ronca, V, 2016) |
| "Primary biliary cholangitis is associated with the development of end-stage liver disease, increased morbidity and mortality." | ( Carey, EJ; Chascsa, D; Lindor, KD, 2017) |
| "Primary biliary cholangitis is a chronic inflammatory, autoimmune cholestatic liver disease, which untreated will usually progress to end-stage biliary cirrhosis." | ( Chapman, RW, 2018) |
| "Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure." | ( Bahar, R; Bowlus, CL; Liu, CH; Wong, KA, 2018) |
| "Primary biliary cholangitis is an archetypal autoimmune disease that causes cholestasis, fibrosis, and liver failure." | ( Hirschfield, GM; Webb, GJ, 2018) |
| "Primary biliary cholangitis is an autoimmune disease affecting the interlobular bile ducts." | ( Alvaro, D; Bassanelli, C; Marzioni, M; Ripellino, C; Urbinati, D, 2019) |
| "Primary biliary cholangitis is a chronic, seropositive and female-predominant inflammatory and cholestatic liver disease, which has a variable rate of progression towards biliary cirrhosis." | ( Gulamhusein, AF; Hirschfield, GM, 2020) |
| "Primary biliary cholangitis is an uncommon cholestatic liver disease predominantly affecting middle-aged women." | ( Chascsa, DMH; Lindor, KD, 2020) |
| "Primary biliary cholangitis is a cholestatic, chronic autoimmune liver disease with a wide individual variation in disease progression." | ( de Veer, RC; Laschtowitz, A; Schramm, C; Van der Meer, AJ, 2020) |
| "Primary biliary cholangitis is a chronic liver disease in which the small bile ducts are progressively destroyed." | ( Erickson, M; Frisch, K; Hofmann, AF; Horsager, J; Keiding, S; Kjærgaard, K; Munk, OL; Schacht, AC; Shapiro, D; Sørensen, M, 2021) |
| "Primary biliary cholangitis is a chronic condition characterised by autoimmune destruction of intralobular bile ducts." | ( Alrubaiy, L; Lambert, JA; Mak, S; Patel, R; Portone, G, 2021) |
| "Primary biliary cholangitis is a chronic autoimmune disease characterized by inflammation and the progressive destruction of small intrahepatic bile ducts." | ( Buchanan-Peart, KA; Levy, C, 2022) |
| "Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis." | ( Barba Bernal, R; Bonder, A; Castro, CM; Ferrigno, B; Goyes, D; Medina Morales, E; Patwardhan, VR; Trivedi, H, 2023) |
| "Primary biliary cholangitis is a chronic progressive cholestatic granulomatous and destructive inflammatory lesion of small intralobular and septal bile ducts that primarily affects women." | ( Balkovec, V; Tomše, P, 2023) |
| Excerpt | Reference |
|---|
| "Of 103 patients with the syndrome of primary biliary cirrhosis (chronic, nonsuppurative destructive cholangitis) who entered a double-blind, randomized, controlled treatment trial with either D-penicillamine or placebo, 21 (20%) were asymptomatic with respect to their liver disease." | ( Dickson, ER; Fleming, CR; Ludwig, J, 1978) |
| "The retention of copper in primary biliary cirrhosis was confirmed by finding abnormally high levels of standard copper measurements in almost all patients before treatment." | ( Baggenstoss, AH; Deering, TB; Dickson, ER; Fleming, CR; Geall, MG; McCall, JT, 1977) |
| "In the primary biliary cirrhosis patients, cholestyramine therapy was associated with significantly lower levels of the vitamin (P less than 0-05)." | ( Beattie, AD; Sherlock, S, 1976) |
| "In a pilot study 5 females with primary biliary cirrhosis (PBC), histological stages I-III, were treated with methotrexate (7." | ( Scheurlen, M; Weber, P; Wiedmann, KH, 1991) |
| "Nine women with symptomatic precirrhotic primary biliary cirrhosis have been treated with oral pulse methotrexate, 15 mg/wk, for 12-34 months." | ( Kaplan, MM; Knox, TA, 1991) |
| "We followed up a group of patients with primary biliary cirrhosis who participated in a 4-yr prospective, double-blind controlled trial of colchicine therapy for 4 additional years." | ( Schaffner, F; Zifroni, A, 1991) |
| "25 serum samples of 22 patients with primary biliary cirrhosis (15 under or after treatment with D-penicillamine) were tested for antibodies against D-penicillamine." | ( Storch, W, 1990) |
| "Primary biliary cirrhosis is a progressive disease of the liver characterized by the immunologic destruction of bile ducts; effective therapy is lacking." | ( Baldus, WP; Dickson, ER; Homburger, HA; Jorgensen, RA; Lindor, KD; Ludwig, J; Wiesner, RH, 1990) |
| "A women with stage I-II primary biliary cirrhosis was treated with ursodeoxycholic acid (UDCA)." | ( Bos, LP; Engels, LG; Wouters, RS, 1990) |
| "To assess the impact of primary biliary cirrhosis on bone mass in general and the relative importance of the stage of the liver disease and of treatment with glucocorticoids for the possible development of osteoporosis, bone mineral mass was measured by single and dual photon absorptiometry in 55 unselected female patients with longstanding primary biliary cirrhosis." | ( Beukers, R; Birkenhäger, JC; Kooij, PP; Pols, HA; Schalm, SW; Van Berkum, FN, 1990) |
| "After 29 patients with primary biliary cirrhosis were treated with ursodeoxycholic acid (750 to 1,000 mg/day) for 6 to 12 mo because of an increase in ursodeoxycholic acid, total plasma bile acids increased from 30." | ( Bircher, J; Endele, R; Fölsch, U; Hopf, U; Klaus, J; Lotterer, E; Möller, B; Raedsch, R; Rudolph, G; Stiehl, A, 1990) |
| "Nine untreated patients with primary biliary cirrhosis, eight patients treated for at least a year with ursodeoxycholic acid and eight control subjects without hepatobiliary disease were compared." | ( Calmus, Y; Gane, P; Poupon, R; Rouger, P, 1990) |
| "We also studied eight patients with primary biliary cirrhosis, treated for more than one and a half years with 600 mg of ursodiol per day." | ( Aikawa, T; Matsuzaki, Y; Osuga, T; Tanaka, N, 1989) |
| "Eighteen patients with primary biliary cirrhosis and 12 patients with chronic hepatitis were treated with 250, 500, and 750 mg of ursodeoxycholic acid per day for three consecutive 2-month periods." | ( Battezzati, PM; Bertolini, E; Crosignani, A; Ghezzi, C; Petroni, ML; Podda, M; Zuin, M, 1988) |
| "Twenty-four patients with primary biliary cirrhosis were entered into a prospective, randomized trial of chlorambucil therapy." | ( Avigan, MI; Campbell, G; Davis, GL; Dusheiko, GM; Hanson, RG; Hoofnagle, JH; Minuk, GY; Pappas, SC; Peters, M; Schafer, DF, 1986) |
| "A patient with primary biliary cirrhosis is reported in whom UV phototherapy alone was repeatedly effective in controlling severe pruritus." | ( Cerio, R; MacDonald, DM; Murphy, GM; Sladen, GE, 1987) |
| "Six patients with primary biliary cirrhosis (PBC) were treated with a daily oral dose of 600 mg rifampicin for 2 weeks to induce the hepatic metabolism of drugs and bile acids." | ( Balzer, K; Dylewizc, P; Goebell, H; Hoensch, HP; Kirch, W; Ohnhaus, EE, 1985) |
| "A 36-yr-old woman with primary biliary cirrhosis developed a Goodpasture's-like syndrome while on D-penicillamine treatment." | ( Kaplan, MM; Matloff, DS, 1980) |
| "A patient with primary biliary cirrhosis (PBC) developed marked hypoprothrombinemia with decreased concentrations of the vitamin K-dependent coagulation factors VII, IX, and X during treatment with rifampicin." | ( Van Steenbergen, W; Vermylen, J, 1995) |
| "We report a case of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome treated with cyclosporine A." | ( Degott, C; Duclos-Vallée, JC; Erlinger, S; Ganne-Carrié, N; Hadengue, A; Robin, E, 1995) |
| "Twenty-two patients with primary biliary cirrhosis were treated with ursodeoxycholic acid, 10 mg/kg per day." | ( Benjaminov, A; Güldütuna, S; Hübner, K; Imhof, M; Leuschner, M; Leuschner, U, 1994) |
| "Effective therapy for primary biliary cirrhosis is lacking but not for want of appropriate immunosuppressive, antifibrotic, and cupruretic agents." | ( Janardan, SK; Moseley, RH, 1994) |
| "For conservative therapy of primary biliary cirrhosis, D-penicillamine is contraindicated and several immunosuppressants investigated are associated with unacceptable side effects; ursodeoxycholic acid, colchicine and perhaps methotrexate seem to be promising, but none has been proven to prolong survival." | ( Renner, EL, 1994) |
| "Seven patients with primary biliary cirrhosis were treated with rifampicin administered for 2 weeks in a daily dose 450-600 mg." | ( Loginov, AS; Petrakov, AV; Reshetniak, VI, 1993) |
| "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy." | ( Ahn, JH; Kim, TH; Peck, KR; Song, YW, 1993) |
| "We treated 6 patients with Stage II primary biliary cirrhosis with cholic acid (CA) 10 mg." | ( Bhatti, S; Güldütuna, S; Hübner, K; Leuschner, M; Leuschner, U; Nickel, A; Wunderlich, N, 1993) |
| "One patient with stage 3 primary biliary cirrhosis had disease progression despite UDCA treatment." | ( Buniak, B; Holt, J; Leevy, CB, 1993) |
| "Effective treatment for primary biliary cirrhosis (PBC) resulting in slower progression and improved survival remains elusive." | ( Lombard, M; Navasa, M; Neuberger, J; Portmann, B; Ranek, L; Ring-Larsen, H; Rodes, J; Trepo, C; Tygstrup, N; Williams, R, 1993) |
| "We conclude that in patients with primary biliary cirrhosis, ursodeoxycholic acid administration replaces endogenous bile acids in the enterohepatic circulation by increasing bile acid fractional turnover rate without significant increments of their hepatic synthesis." | ( Aldini, R; Bazzoli, F; Cipolla, A; Festi, D; Mazzella, G; Parini, P; Polimeni, C; Roda, A; Tonelli, D; Villanova, N, 1993) |
| "Treatment of patients with primary biliary cirrhosis (PBC) using ursodeoxycholic acid (UDCA) leads to a reduction in serum bilirubin." | ( Bailey, RJ; Blendis, LM; Cauch-Dudek, K; Ghent, CN; Heathcote, EJ; Kilmurry, MR; Minuk, GY; O'Rourke, K; Pappas, SC; Scully, LJ; Steinbrecher, UP; Sutherland, LR; Williams, CN; Worobetz, LJ, 1996) |
| "In the treatment of patients with primary biliary cirrhosis (PBC), methotrexate (MTX) and ursodeoxycholic acid (UDCA) have both been associated with clinical, biochemical, and histologic improvement." | ( Desmet, V; Fevery, J; Sciot, R; Van Eyken, P; Van Steenbergen, W, 1996) |
| "Fifteen female patients with primary biliary cirrhosis were followed for 1 year and were then treated with UDCA (600 mg/day) for another year." | ( Ikeda, T; Kobayashi, F; Marumo, F; Noguchi, O; Sakamoto, S; Sato, C; Tozuka, S, 1996) |
| "Twenty-two patients with primary biliary cirrhosis treated with ursodeoxycholic acid (600 mg/day) for 30 months were randomly assigned to two groups: group 1, colchicine (1 mg/day) and ursodeoxycholic acid (n = 10); group 2, ursodeoxycholic acid alone (n = 12)." | ( Ikeda, T; Kobayashi, F; Marumo, F; Noguchi, O; Sakamoto, S; Sato, C; Tozuka, S, 1996) |
| "The apparent coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis in the same patient raises unresolved problems for nosology and therapy." | ( Feeney, SJ; Hara, K; Ikuno, N; Mackay, IR; Matsuo, I; Omagari, K; Shirono, K; Whittingham, S, 1996) |
| "Its emerging role in the treatment of primary biliary cirrhosis and inflammatory bowel disease still requires further evaluation." | ( Neuberger, J; Tang, H, 1996) |
| "Twelve primary biliary cirrhosis patients (all Child-Pugh Class A), treated with prednisone in the context of a 1-year placebo-controlled pilot study with prednisone (maintenance dose 10 mg daily), and azathioprine (50 mg daily), were randomized to receive either cyclical etidronate (400 mg daily, during 2 weeks) alternated with calcium 500 mg daily during 11 weeks or calcium alone." | ( den Ouden, JW; Hop, WC; Pols, HA; Schalm, SW; van Buuren, HR; van Leeuwen, JP; Wolfhagen, FH, 1997) |
| "Treatment of primary biliary cirrhosis with ursodiol or colchicine may stabilize the disease or slow its rate of progression, but no reports of spontaneous or treatment-related remission have been published." | ( DeLellis, RA; Kaplan, MM; Wolfe, HJ, 1997) |
| "To determine whether primary biliary cirrhosis fully responds to low-dose oral methotrexate therapy." | ( DeLellis, RA; Kaplan, MM; Wolfe, HJ, 1997) |
| "Pharmacotherapy of primary biliary cirrhosis (PBC) was not resolved unequivocally so far." | ( Brodanová, M; Perlík, F, 1997) |
| "The present data show that in primary biliary cirrhosis the epsilon2 allele is overrepresented, and suggest that the expression of primary biliary cirrhosis and response of the disease to ursodeoxycholic acid treatment are closely related to the apo E polymorphism." | ( Färkkilä, M; Gylling, H; Karvonen, AL; Lehtola, J; Leino, R; Makinen, J; Mattila, J; Miettinen, TA; Tilvis, R; Vuoristo, M, 1997) |
| "Primary biliary cirrhosis (PBC) is a rare chronic cholestatic disorder of unknown origin that can now be treated effectively with ursodeoxycholic acid (UDCA)." | ( Beste, M; Breuer, N; Goebell, H; v Schönfeld, J; Zotz, RB, 1997) |
| "UDCA-treatment in primary biliary cirrhosis is now recommended in several countries, for example in the U." | ( Boberg, KM; Schrumpf, E, 1997) |
| "Primary biliary cirrhosis should be included in the differential diagnosis of recurrent arthritis and erythema nodosum, as early treatment with ursodeoxycholic acid can favourably influence its course." | ( Fiedler, GM; Grunewald, RW; Müller, GA; Schauer, A; Stöckmann, F, 1997) |
| "Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study." | ( Hagey, LR; Hofmann, AF; Jorgensen, RA; Lindor, KD; Ricci, P; Rolland Dickson, E, 1998) |
| "The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown." | ( Chazouillères, O; Montembault, S; Poupon, R; Rosmorduc, O; Serfaty, L; Wendum, D, 1998) |
| "Ursodeoxycholic acid therapy in primary biliary cirrhosis reduces cholestasis and prolongs transplant-free survival; no other drugs are of proven efficacy in primary biliary cirrhosis, and none have any benefit on the disease progression of primary sclerosing cholangitis." | ( Hay, JE, 1998) |
| "Nine of the 30 patients with primary biliary cirrhosis underwent a second liver biopsy for evaluation of the ursodeoxycholic acid treatment." | ( Noguchi, K; Sakisaka, S; Sasatomi, K; Sata, M; Tanikawa, K, 1998) |
| "Since primary biliary cirrhosis has many features of an autoimmune disorder, immunosuppressives added to ursodeoxycholic acid may be of value in the treatment of primary biliary cirrhosis." | ( de Vries, RA; den Ouden, JW; Hop, WC; Kerbert, MJ; Schalm, SW; Smit, AM; ten Kate, FJ; van Berge-Henegouwen, GP; van Buuren, HR; van der Hoek, EW; van Hoogstraten, HJ; van Lijf, HH; van Zanten, RA; Wolfhagen, FH, 1998) |
| "In patients with primary biliary cirrhosis receiving ursodeoxycholic acid, there is an additional beneficial effect of 1-year treatment with prednisone and azathioprine on symptoms and biochemical, fibrogenetic and histological parameters." | ( de Vries, RA; den Ouden, JW; Hop, WC; Kerbert, MJ; Schalm, SW; Smit, AM; ten Kate, FJ; van Berge-Henegouwen, GP; van Buuren, HR; van der Hoek, EW; van Hoogstraten, HJ; van Lijf, HH; van Zanten, RA; Wolfhagen, FH, 1998) |
| "In 26 patients with primary biliary cirrhosis stage II, III or IV, therapy showed a trend to improved survival, but this was still significantly worse than the general population." | ( Bateson, MC; Gedling, P, 1998) |
| "Diagnosis of primary biliary cirrhosis was made and the patients were treated with UDCA." | ( Castro Fernández, M; Grande, L; Nevado Santos, M; Núñez, J; Otero Fernández, MA; Romero Gómez, M; Suárez García, E; Wichmann, I, 1999) |
| "New treatments for primary biliary cirrhosis (PBC) need to be evaluated." | ( Giaffer, MH; Gleeson, D; Hendrickse, MT; Rigney, E; Soomro, I; Triger, DR; Underwood, JC, 1999) |
| "Evidence of autoimmunity in primary biliary cirrhosis (PBC) provides a rationale for treatment with an immunosuppressant." | ( Chamuleau, RA; Houben, M; Jones, EA; Reesink, HW; ten Kate, FJ; ter Borg, F, 1999) |
| "Seventy patients with primary biliary cirrhosis were treated with ursodeoxycholic acid 10-15 mg/kg/day and followed up for 6-13 years." | ( Ackermann, H; Dietrich, CF; Herrmann, G; Leuschner, M; Leuschner, U; Raedle, J; Seidl, C; You, T, 2000) |
| "In patients with mainly early stages of primary biliary cirrhosis, higher values of alkaline phosphatase and gamma glutamyl transpeptidase are the only biochemical indexes which allow discrimination between patients who will completely or incompletely respond to ursodeoxycholic acid treatment." | ( Ackermann, H; Dietrich, CF; Herrmann, G; Leuschner, M; Leuschner, U; Raedle, J; Seidl, C; You, T, 2000) |
| "Primary biliary cirrhosis patients were treated with ursodeoxycholic acid, prednisone and the association of the two drugs for three 4-week periods, each period separated by a 4-week wash-out." | ( Fracchia, M; Galatola, G; Pera, A; Secreto, P; Tabone, M; Zaffino, C, 2000) |
| "Osteoporosis is a common complication of primary biliary cirrhosis but there is no accepted therapy for the osteoporosis." | ( Dickson, ER; Jorgensen, RA; Khosla, S; Lindor, KD; Tiegs, RD, 2000) |
| "Treatment of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) with ursodeoxycholic acid (UDCA) has been in common use since 1985." | ( Holtmeier, J; Leuschner, U, 2001) |
| "Primary biliary cirrhosis is a rare autoimmune liver disease and an effective treatment has been difficult to establish." | ( Christensen, E; Gluud, C, 2002) |
| "Primary biliary cirrhosis-associated bone loss was significantly related to postmenopausal estrogen deficiency, and efficiently prevented by hormonal replacement therapy." | ( Berenbaum, F; Chazouillères, O; Grandpierre, C; Le Gars, L; Poupon, R, 2002) |
| "Approximately 20-30% of patients with primary biliary cirrhosis (PBC) respond fully to treatment with ursodeoxycholic acid (UDCA)." | ( Kaplan, MM; Lee, YM, 2003) |
| "Forty-two post-menopausal women with primary biliary cirrhosis were treated with calcium and vitamin D, either alone (n = 21) or together with transdermal hormone replacement therapy (n = 21)." | ( Abraha, H; Buxton-Thomas, M; Moniz, C; O'Donohue, J; Pereira, SP; Phillips, MG; Williams, R, 2004) |
| "In primary biliary cirrhosis patients, the prevalence of IgM anti-lipid A antibodies was higher before than after ursodeoxycholic acid therapy (64% vs 22%, respectively; P<0." | ( Ballot, E; Bandin, O; Chazouilleres, O; Johanet, C; Poupon, R, 2004) |
| "Primary biliary cirrhosis frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy." | ( Bonis, PA; Cheng, S; Kaplan, MM; Price, LL, 2004) |
| "To investigate the clinical features of primary biliary cirrhosis (PBC) and its treatment by integrated traditional Chinese and western medicine." | ( He, M; Jiang, J, 2003) |
| "We evaluated 209 consecutive primary biliary cirrhosis patients, 69 compliant with ursodeoxycholic acid and 140 untreated [mean follow-up 5." | ( Burroughs, AK; Carpenter, JR; Chan, CW; Feudjo, M; Gunsar, F; Rigamonti, C; Vlachogiannakos, J, 2005) |
| "Increased ET-2 is an early defect in primary biliary cirrhosis that is significantly reduced by the ursodeoxycholic acid treatment." | ( Dimoulios, P; Kolios, G; Koulentaki, M; Kouroumalis, A; Kouroumalis, E; Matrella, E; Notas, G; Tsagarakis, N; Xidakis, C, 2005) |
| "Twelve patients with early-stage primary biliary cirrhosis and eight healthy volunteers were treated with UDCA (15 mg/kg daily) for 3 weeks and subsequently with rifampicin (600 mg/d) for 1 week." | ( Beuers, U; Denk, A; Dilger, K; Heeg, MH, 2005) |
| "Whether primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome requires immunosuppressive therapy in addition to ursodeoxycholic acid (UDCA) is a controversial issue." | ( Chazouillères, O; Poupon, R; Rosmorduc, O; Serfaty, L; Wendum, D, 2006) |
| "We treated eight consecutive primary biliary cirrhosis patients with methotrexate who were followed in a single hepatology clinical practice, who were symptomatic, and who had had an incomplete biochemical response to ursodeoxycholic acid therapy." | ( Babatin, MA; Sanai, FM; Swain, MG, 2006) |
| "In conclusion, in children with biliary cirrhosis and FUO on the waiting list for liver transplantation, information obtained by FDG-PET imaging may be useful for decisions on therapy and suitability for liver transplantation." | ( Gouw, AS; Porte, RJ; Pruim, J; Rings, EH; Schölvinck, EH; Sturm, E, 2006) |
| "Primary biliary cirrhosis (PBC) is an organ-specific autoimmune disease that predominantly affects women and is characterized by chronic, progressive destruction of small intrahepatic bile ducts with portal inflammation and ultimately fibrosis, leading to liver failure in the absence of treatment." | ( Reshetnyak, VI, 2006) |
| "We conducted a prospective study in primary biliary cirrhosis with a view to optimizing the rationale for the medical treatment of bone loss." | ( Baldo, V; Camozzi, V; Carderi, I; Ferrara, F; Floreani, A; Luisetto, G; Rizzotto, ER, 2007) |
| "For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment." | ( Gershwin, ME; Ishibashi, H; Komori, A; Shimoda, S, 2007) |
| "Rats with secondary biliary cirrhosis [bile duct ligation (BDL)] were treated with AVE 9488." | ( Biecker, E; Heller, J; Hennenberg, M; Kang, A; Sauerbruch, T; Trebicka, J, 2008) |
| "Primary biliary cirrhosis (PBC) is a poorly understood disease, both in terms of its pathogenesis and the mechanism of action of its most common treatment, ursodeoxycholic acid (UDCA)." | ( Borozan, I; Chen, L; Coltescu, C; Edwards, AM; Guindi, M; Heathcote, EJ; McGilvray, ID; Meng, X; Milkiewicz, P; Ostrowski, MA; Sun, J, 2008) |
| "The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered." | ( Abbas, G; Lindor, KD, 2010) |
| "Up to one-third of patients with primary biliary cirrhosis (PBC) experience recurrent disease following liver transplantation, which is associated with earlier and more severe recurrence in patients treated with tacrolimus as compared with cyclosporine A (CsA)." | ( Bintner, J; Mason, AL; Montano-Loza, AJ; Wasilenko, S, 2010) |
| "Treatment of primary biliary cirrhosis is complicated." | ( Bjelakovic, G; Gluud, C; Krstic, MN; Poropat, G; Rudic, JS, 2012) |
| "Primary biliary cirrhosis (PBC) is an inflammatory autoimmune liver disease leading, if untreated, to cholestasis and cirrhosis." | ( Rautiainen, H, 2012) |
| "Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure." | ( Czul, F; Levy, C; Peyton, A, 2013) |
| "For patients with primary biliary cirrhosis (PBC) with features of autoimmune hepatitis (AIH), treatment with ursodeoxycholic acid (UDCA) alone or in combination with immunosuppression is controversial." | ( Bresson-Hadni, S; Efe, C; Heurgué-Berlot, A; Kav, T; Masi, C; Muratori, L; Muratori, P; Ozaslan, E; Purnak, T; Schiano, TD; Thiéfin, G; Ustündag, Y; Wahlin, S, 2014) |
| "Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U." | ( Bowlus, CL; Cazzagon, N; Floreani, A; Franceschet, I; Gershwin, ME; Perini, L, 2015) |
| "All patients with primary biliary cirrhosis (PBC) and abnormal liver biochemistry should be considered for specific therapy." | ( Czul, F; Levy, C, 2016) |
| "Age at presentation with primary biliary cholangitis (PBC) is associated with differential response to ursodeoxycholic acid (UDCA) therapy." | ( Alexander, G; Bathgate, A; Ducker, SJ; Dyson, JK; Heneghan, MA; Hirschfield, GM; Jones, DE; Jopson, L; Mells, G; Neuberger, J; Sandford, R; Stocken, D; Wilkinson, N, 2016) |
| "Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications." | ( Kremer, AE; Vetter, M, 2018) |
| "Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression." | ( Abergel, A; Admane, FH; Boursier, J; Bronowicki, JP; Chazouillères, O; Chollet-Martin, S; Corpechot, C; de Chaisemartin, L; de Ledinghen, V; Debette-Gratien, M; Gaouar, F; Goria, O; Habersetzer, F; Heurgue-Berlot, A; Humbert, L; Larrey, D; Le Gruyer, A; Lefèvre, G; Lemoinne, S; Mathurin, P; Minello, A; Nguyen-Khac, E; Nkontchou, G; Ollivier-Hourmand, I; Potier, P; Poupon, R; Rainteau, D; Rousseau, A; Roux, O; Silvain, C; Simon, T; Zarski, JP; Zoulim, F, 2018) |
| "Among patients with primary biliary cholangitis who had had an inadequate response to ursodeoxycholic acid alone, treatment with bezafibrate in addition to ursodeoxycholic acid resulted in a rate of complete biochemical response that was significantly higher than the rate with placebo and ursodeoxycholic acid therapy." | ( Abergel, A; Admane, FH; Boursier, J; Bronowicki, JP; Chazouillères, O; Chollet-Martin, S; Corpechot, C; de Chaisemartin, L; de Ledinghen, V; Debette-Gratien, M; Gaouar, F; Goria, O; Habersetzer, F; Heurgue-Berlot, A; Humbert, L; Larrey, D; Le Gruyer, A; Lefèvre, G; Lemoinne, S; Mathurin, P; Minello, A; Nguyen-Khac, E; Nkontchou, G; Ollivier-Hourmand, I; Potier, P; Poupon, R; Rainteau, D; Rousseau, A; Roux, O; Silvain, C; Simon, T; Zarski, JP; Zoulim, F, 2018) |
| "The aims of treatment and management of primary biliary cholangitis are the amelioration of associated symptoms, particularly pruritis and fatigue, and the prevention of end-stage liver disease." | ( Chapman, RW, 2018) |
| "To describe primary biliary cholangitis epidemiology and investigate treatment patterns for Italian patients with this disease." | ( Alvaro, D; Bassanelli, C; Marzioni, M; Ripellino, C; Urbinati, D, 2019) |
| "What's already known about this topic? Primary biliary cholangitis (PBC) is frequently associated with intractable pruritus for which current treatment options are often unsuccessful." | ( Hegade, VS; Hussain, AB; Jones, DE; Reynolds, NJ; Samuel, R, 2019) |
| "New treatments for primary biliary cholangitis (PBC) are progressively emerging, including first and second generations of farnesoid X receptor and peroxisome proliferator-activated receptors agonists." | ( Corpechot, C, 2019) |
| "Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-line treatment with ursodeoxycholic acid." | ( Kowdley, KV; Shah, RA, 2020) |
| "We reviewed the medical records of primary biliary cholangitis patients who were diagnosed by liver biopsy and treated with the corresponding treatment." | ( Qian, JD; Wang, GQ; Wang, Y; Yao, TT, 2020) |
| "Thirty-eight primary biliary cholangitis patients received UDCA monotherapy (group A), and another 42 patients received UDCA, prednisolone and immunosuppressant triple therapy (group B)." | ( Qian, JD; Wang, GQ; Wang, Y; Yao, TT, 2020) |
| "Around one-third of patients with primary biliary cholangitis (PBC) needs additional medical therapy alongside ursodeoxycholic acid (UDCA) treatment." | ( Bergquist, A; Beuers, U; Drebber, U; Färkkilä, M; Greinwald, R; Hirschfield, GM; Kupcinskas, L; Manns, MP; Ott, P; Parés, A; Poupon, R; Pröls, M; Spengler, U; Stiess, M; Wendum, D, 2021) |
| "Patients with primary biliary cholangitis (a rare chronic liver disease) that do not respond to standard therapy remain at risk of disease progression toward cirrhosis and impaired quality of life." | ( Birman, P; Bonder, A; Caldwell, S; Hanf, R; Heneghan, MA; Hirschfield, GM; Jones, D; Kowdley, KV; Levy, C; Luketic, V; Magrez, D; Megnien, S; Pares, A; Pratt, D; Schattenberg, JM; Staels, B; Tailleux, A; Vierling, J, 2021) |
| "The current standard of treatment in primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), although a considerable proportion of patients show incomplete response resulting in disease progression." | ( Agostinho, C; Alexandrino, G; Alves, AL; Andreozzi, V; Banhudo, A; Calinas, F; Carvalho, J; Coelho, M; Cortez-Pinto, H; Cotrim, I; Dias, T; Figueiredo, P; Gomes, MV; Gouveia, C; Leal, C; Liberal, R; Lopes, S; Loureiro, R; Machado, MV; Maia, L; Martins, A; Mesquita, M; Nunes, J; Oliveira, J; Pedroto, I; Pinto, JS; Presa, J; Santos, A; Vale, AHE, 2021) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "There is no licensed therapy for primary biliary cholangitis-related fatigue; treating underlying causes where applicable is recommended." | ( Alrubaiy, L; Lambert, JA; Mak, S; Patel, R; Portone, G, 2021) |
| "Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant." | ( Mayo, MJ, 2022) |
| "Across the population of patients with primary biliary cholangitis in the United Kingdom, rates of biochemical response and drug discontinuation appear similar under fibric acid and OCA treatment." | ( Abbas, N; Aspinall, R; Chimakurthi, CR; Crothers, H; Culver, EL; Dyson, JK; Halliday, N; Hegade, V; Hirschfield, G; Jones, D; Jones, R; Kallis, Y; Khakoo, SI; McCune, A; Mells, G; Orrell, M; Patanwala, I; Phaw, A; Smith, B; Thain, C; Thain, RM; Thorburn, D; Trivedi, PJ, 2023) |
| "A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment." | ( Bäckström, T; Corrigan, M; Doverskog, M; Dyson, JK; Hegade, VS; Johansson, M; Jones, DEJ; Jopson, L; Mells, G; Ogle, L; Palmer, J; Wetten, A, 2022) |
| "A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment." | ( Bäckström, T; Corrigan, M; Doverskog, M; Dyson, JK; Hegade, VS; Johansson, M; Jones, DEJ; Jopson, L; Mells, G; Ogle, L; Palmer, J; Wetten, A, 2022) |
| "Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score." | ( Battezzati, PM; Bruns, T; Corpechot, C; Dalekos, GN; de Veer, RC; Floreani, A; Gatselis, NK; Goet, JC; Hansen, BE; Harms, MH; Hirschfield, GM; Invernizzi, P; Janssen, HLA; Kowdley, KV; Lammers, WJ; Lindor, KD; Mason, AL; Mayo, MJ; Nevens, F; Parés, A; Ponsioen, CY; Thorburn, D; Trivedi, PJ; van der Meer, AJ; van Hooff, MC; Verhelst, X, 2023) |
| "There is a real unmet need for primary biliary cholangitis (PBC) treatments that can improve quality of life impacting symptoms." | ( Carbone, M; Invernizzi, P; Jones, D; Levy, C; Little, N; Nevens, F; Swain, MG; Wiesel, P, 2023) |
| "In patients with primary biliary cholangitis (PBC), the serum liver biochemistry measured during treatment with ursodeoxycholic acid-the UDCA response-accurately predicts long-term outcome." | ( Badrock, J; Clark, G; Cordell, HJ; Hirschfield, GM; Jones, DE; Jones, RL; Kotagiri, P; Liaskou, E; Martin, JE; Mells, GF; Mulcahy, V; Rushbrook, SM; Ryder, SD; Sandford, RN; Taylor-Robinson, SD; Thorburn, D, 2023) |
| "Patients with primary biliary cholangitis (PBC) and insufficient response to ursodeoxycholic acid (UDCA), currently assessed after 1 year, are candidates for second-line therapy." | ( Battezzati, PM; Bruns, T; Carbone, M; Cazzagon, N; Corpechot, C; Dalekos, GN; Floreani, A; Gatselis, NK; Gulamhusein, A; Hansen, BE; Hassanally, I; Hirschfield, GM; Invernizzi, P; Ioannou, S; Janssen, HLA; Kowdley, KV; Lammers, WJ; Levy, C; Lindor, KD; Lleo, A; Londoño, MC; Mason, AL; Mayo, MJ; Murillo Perez, CF; Nevens, F; Parés, A; Ponsioen, CY; Thorburn, D; Trivedi, PJ; van der Meer, AJ; Verhelst, X; Vuppalanchi, R, 2023) |
| "Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus." | ( Andreone, P; Aspinall, RJ; Boudes, PF; Bowlus, CL; Choi, YJ; Corpechot, C; Dalekos, GN; Drenth, JPH; Fassio, E; Forman, L; Gonzalez-Huezo, MS; Gordon, SC; Gulamhusein, A; Heneghan, MA; Hinrichsen, H; Hirschfield, GM; Invernizzi, P; Janczewska, E; Jeong, SH; Jones, DEJ; Kowdley, KV; Kremer, AE; Ladrón de Guevara, AL; Lawitz, EJ; Leggett, BA; Levy, C; Mayo, MJ; McWherter, CA; Nevens, F; Pratt, DS; Raikhelson, K; Ryder, SD; Shiffman, ML; Steinberg, A; Swain, MG; Trivedi, PJ; Vargas, V; Vierling, JM; Zigmond, E; Zuckerman, E, 2023) |
| "A total of 257 primary biliary cholangitis (PBC) patients treated with UDCA (13-15 mg/kg/d) were enrolled in this retrospective study." | ( He, H; Lei, H; Tai, W; Yang, J; Zheng, M; Zhu, H, 2023) |